Clinical Trial Update: Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC [Phase 2]

View source ↗

Summary

Phase 2 trial of RAD001 (everolimus) with transarterial chemoembolization for localized unresectable hepatocellular carcinoma has been terminated; results have …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• RAD001 (Everolimus) (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2017-05-03